Stock Information
symbol line chart

LLYLilly(Eli) & Co

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

David A. Ricks

Location

Indiana, USA

Exchange

NYSE

Website

https://lilly.com

Summary

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

Company Info

CEO

David A. Ricks

Location

Indiana, USA

Exchange

NYSE

Website

https://lilly.com

Summary

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

AI Insights for LLY
2 min read

Quick Summary

Eli Lilly and Company is a leading global pharmaceutical company headquartered in Indianapolis, Indiana, USA. The company specializes in discovering, developing, and marketing innovative medications, primarily focusing on human pharmaceuticals for a wide range of conditions. Lilly serves healthcare providers, hospitals, and pharmacies worldwide, targeting both primary care markets and specialized medical fields. The firm is particularly strong in areas such as diabetes, obesity, oncology, immunology, and neuroscience, and has gained significant recognition for its pioneering work in diabetes and weight-loss drugs. Lilly's customer base includes patients, healthcare professionals, governments, and health systems globally.

The Bull Case

  • Eli Lilly’s primary strengths lie in its best-in-class innovation pipeline, particularly for diabetes, obesity, and neurodegenerative diseases.
  • The firm enjoys a dominant market position, benefiting from early mover advantage in GLP-1 therapies and blockbuster product launches like Mounjaro and Zepbound.
  • Strong financials, significant gross profit margins, and expanding global footprint reinforce investor confidence.
  • The management team is experienced and has consistently demonstrated the ability to pivot towards high-growth therapeutic areas.
  • Furthermore, Lilly's brand is trusted worldwide, and its diversified portfolio reduces overall business risk.

The Bear Case

  • The company’s high Price-to-Earnings (P/E) ratio and elevated valuation multiples raise concerns about overpricing relative to current earnings.
  • Recent operational challenges, such as inventory constraints, have led to missed earnings targets and downward revisions of guidance, impacting investor sentiment.
  • Lilly is also exposed to increased competition from generics in cost-sensitive markets like India, which could threaten margins.
  • The company’s low dividend yield may make it less attractive to income-focused investors.
  • Regulatory risks and potential delays in bringing new drugs to market could further hamper near-term performance.

Key Risks

  • Key risks for Eli Lilly include intensifying competition from both branded rivals (such as Novo Nordisk) and generics, which could undermine pricing power and share.
  • Regulatory setbacks or adverse trial outcomes could delay or prevent the commercialization of new drugs, hurting revenue projections.
  • Slower-than-expected demand for flagship therapies, especially if the GLP-1 drug market fails to meet growth expectations, would threaten Lilly’s financial performance and stock price.
  • Operational challenges, including supply chain or manufacturing issues, could further impact sales.

What to Watch

UpcomingDuring the most recent quarter, Eli Lilly launched an easy-to-use injector pen for Mounjaro in India, expanding its reach in high-potential markets despite increased competition from generics.
UpcomingThe company conducted and reported results from the SURPASS-CVOT clinical trial, where Mounjaro outperformed Trulicity in cardiovascular outcomes.
UpcomingEarnings and sales for Q3 2024 missed analyst estimates, primarily due to inventory issues and lower-than-expected sales from flagship drugs Mounjaro and Zepbound.
ExpectedFor the upcoming quarter, analysts and management anticipate stronger performance driven by expanding sales and new product launches in diabetes and obesity care.

Price Drivers

  • Eli Lilly’s stock price is primarily driven by the commercial success and expansion of its best-selling drugs, especially Mounjaro and Zepbound for diabetes and weight loss.
  • Ongoing innovation, late-stage clinical trial outcomes, and regulatory milestones deeply influence investor sentiment.
  • Macroeconomic events, such as healthcare policies, drug reimbursement rates, and global obesity trends, also impact the company’s valuation.
  • The release of quarterly earnings, product launches, and updates on the production capacity are key determinants of short-term price movements.

Recent News

  • Recent news highlights several important developments for Eli Lilly.
  • The launch of the Mounjaro injector pen in India marks a significant push into large emerging markets, but also signals heightened competition against cheaper generics.
  • Shares have experienced volatility, falling after Q3 2024 earnings and sales missed expectations, prompting management to lower guidance for the year.
  • Nonetheless, positive clinical trial results for Mounjaro and large-scale analyst upgrades (including a $1,300 price target) underscore strong future potential, especially in obesity management.

Market Trends

  • Broader market trends influencing Eli Lilly include surging global prevalence of diabetes and obesity, fueling demand for advanced therapeutics.
  • The pharmaceutical sector is experiencing rapid innovation, particularly in metabolic and cardiovascular health, with GLP-1 agonists at the forefront.
  • There is intensifying competition among major players to bring next-generation treatments to market, as seen in recent clinical advancements by both Lilly and Novo Nordisk.
  • Investors are increasingly focusing on large-cap, innovation-driven healthcare stocks, but there’s also competitive capital allocation toward technology and AI sectors.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on LLY

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@AlexWalker 1 month ago

These stocks are making big moves today

These stocks are making big moves today

, , and several other names are grabbing attention after posting some of the market's biggest moves. Whether it's earnings, analyst updates, or company-specific news, investors are showing once again that individual stock stories can still drive massive gains and losses even when the broader market is relatively calm.

avatar
@EmmaStone 1 month ago

One healthcare giant and one battery stock are stealing the spotlight

One healthcare giant and one battery stock are stealing the spotlight

and found themselves among the market's biggest movers as investors reacted to fresh company developments and shifting sentiment. Whether it's healthcare innovation or next-generation battery technology, traders are showing they're still willing to chase strong stories when momentum starts building.

avatar
@BrianHoward 1 month ago

Seeing strong moves from Eli Lilly

Seeing strong moves from Eli Lilly

It is really interesting to see how continues to lead the healthcare sector as investors look for more stable growth options. Do you think their current lead in the obesity and diabetes market is sustainable for the long term or is the valuation getting a bit too high now?

avatar
@BrianHoward 1 month ago

Eli Lilly continues to lead

Eli Lilly continues to lead

it is really interesting to see how eli lilly continues to lead the healthcare sector with such steady growth. do you think the market will keep valuing at a premium because of their obesity and diabetes drugs? i would love to know if you guys think there is still room for more upside here.

avatar
@BrianHoward 1 month ago

Eli Lilly showing real strength

Eli Lilly showing real strength

it is pretty impressive to see how Eli Lilly stays so resilient while investors look for more stable growth names right now. i wonder if the demand for their diabetes and obesity treatments will keep moving higher regardless of what the broader market does. what do you all think about their current pipeline?

avatar
@FallenBlew41 1 month ago

Recession Incoming? Here's Why I'm Still Buying

Recession Incoming? Here's Why I'm Still Buying

Recession talk is loud again. Honestly? I'm not that stressed.

Markets price in fear way before the data catches up. And unemployment's still solid, earnings keep surprising...... , , aren't flinching.

Recessions happen. They're also when the best deals show up.

Are you sitting in cash right now or quietly building a list? What sectors are you watching?

avatar
@BrianHoward 1 month ago

Eli Lilly Growth Trends

Eli Lilly Growth Trends

It's really interesting to see Eli Lilly climbing while people look for more stable growth options lately. Do you think the momentum for can stay this strong through the rest of the year?

avatar
@BrianHoward 1 month ago

Checking in on Eli Lilly

Checking in on Eli Lilly

it's really impressive to see how eli lilly keeps climbing while other sectors are so volatile. the obesity drug pipeline for seems like such a solid anchor for long-term growth right now. do you guys think it's still a good time to get in?

avatar
@BrianHoward 1 month ago

Eli Lilly and the pharma growth story

Eli Lilly and the pharma growth story

i've been watching Eli Lilly lately and it's impressive how they dominate the market without being an ai company. do you think still has plenty of room to run as more people focus on healthcare staples?

avatar
@BrianHoward 1 month ago

Eli Lilly and the pharma growth story

Eli Lilly and the pharma growth story

i've been watching Eli Lilly lately and it's impressive how they dominate the market without being an ai company. do you think still has plenty of room to run as more people focus on healthcare staples?